Higher Baseline Lactate Dehydrogenase and History of Allergic Rhinitis as Predictive Factors of Conjunctivitis in Atopic Dermatitis Patients Treated with Tralokinumab
Restricted accessLetterFirst published online November, 2025
Higher Baseline Lactate Dehydrogenase and History of Allergic Rhinitis as Predictive Factors of Conjunctivitis in Atopic Dermatitis Patients Treated with Tralokinumab
HallingAS, LoftN, SilverbergJI, et al.Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol. 2021; 84(1):139–147.
2.
PezzoloE, SchenaD, GambardellaA, et al.Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicenter real-world study. J Eur Acad Dermatol Venereol. 2024; 38(1):e11–e13.
3.
HaginoT, OndaM, SaekiH, et al.Effects of tralokinumab on clinical and laboratory indexes in Atopic Dermatitis: A 24-week real-world study. Dermatitis. 2024.
4.
AkinladeB, Guttman-YasskyE, de Bruin-WellerM, et al.Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019; 181(3):459–473.
5.
UchidaH, KamataM, NagataM, et al.Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting. J Am Acad Dermatol. 2020; 82(5):1247–1249.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
